Gastric bypass associated with reduced risk for psoriasis, psoriatic arthritis
There was a significantly reduced risk for new-onset and progression of psoriasis and psoriatic arthritis associated with gastric bypass in patients undergoing bariatric surgery, but gastric banding did not have the same association.
Researchers used data from the Danish National Patient Registry to identify all Danish citizens who underwent gastric bypass or gastric banding between Jan. 1, 1997 and Dec. 31, 2012.
Data was analyzed between Feb. 4 to April 14, 2016.
There were 12,364 patients (76.7% women) receiving gastric bypass and 1,071 patients (74.7% women) receiving gastric banding included in the study. The mean age of patients in the gastric bypass cohort was 27.8 years at the study start and 41 years at the time of surgery. Mean age of patients in the gastric banding cohort was 32.3 years at the study start and 41.7 years at time of surgery.
New-onset incidence rates per 1,000 person-years were determined, with adjusted hazard rations (HRs) estimated.
Gastric bypass had an adjusted HR of psoriasis of 0.52 (95% CI, 0.33-0.81), while gastric banding had an adjusted HR of 1.23 (95% CI, 0.4-3.75).
Progression to severe psoriasis had an adjusted HR of 0.44 (95% CI, 0.23-0.86) for the gastric bypass cohort and adjusted HR of 1.18 (95% CI, 0.12-11.49) for gastric banding.
Gastric bypass had an adjusted HR for psoriatric arthritis of 0.29 (95% CI, 0.12-0.71) while gastric bypass banding had an adjusted HR of 0.53 (95% CI, 0.08-3.56).
“Gastric bypass was associated with a significantly reduced risk and improved prognosis of psoriasis and psoriatic arthritis, whereas gastric banding was not,” the researchers concluded. “Although speculative, these findings may be the result of post-operative differences in weight loss and nutrient uptake as well as differences in the postsurgical secretion of a number of gut hormones, including GLP-1.” – by Bruce Thiel
Disclosure: Egeberg reports receiving research funding and/or consultancy honoraria form Pfizer and Eli Lilly. Please see the full study for a list of other researchers’ relevant financial disclosures.